Read about our 4 hour rapid WGS collaboration!

Learn More

Short-Read vs. Long-Read WGS: Choosing the Right Sequencing Approach

Short-Read vs. Long-Read WGS: Which is Right for Your Next Project? 

 

Key Takeaways:  

  • Your sequencing strategy decision impacts downstream analysis and research outcomes 
  • Short-read sequencing enables cost-efficient analysis of large cohorts with high accuracy 
  • Long-read sequencing resolves structural complexity and repetitive regions 
  • Study scale, budget, timelines, and research questions guide technology selection  
  • Hybrid strategies combining both technologies can maximize research insights while managing costs 

 

One Human Genome, Multiple Paths to Discovery 

With increasing accessibility to human whole genome sequencing, research and clinical scientists face an important strategic decision: which sequencing approach will best serve their study objectives? Modern genomic technologies offer multiple paths to discovery, each revealing different aspects of genome variation. Access to several types of genomic analysis empowers researchers to ask more and increasingly complex questions, but this expanded access has also complicated the strategic decision-making process for research teams. The sequencing strategy you select shapes what variants you’ll detect, how you’ll interpret them, and ultimately, what questions you can answer downstream. 

 Understanding the primary differences between short-read and long-read WGS technologies is essential for maximizing research impact. These approaches offer complementary windows into genome variation, each excelling in distinct research contexts. The key to selecting the right approach lies in aligning the technology with your research questions, understanding the variant types most critical to your investigation, and considering practical factors such as study scale and budget constraints. 

 

The Core Difference: Read Length Shapes What You Can See 

The primary difference between short-read and long-read sequencing centers on read length, or how much continuous genetic sequence is captured and analyzed at once. This parameter fundamentally shapes the observable genomic landscape. 

Short-read sequencing technologies generate reads that are hundreds of base pairs in length.1 This approach delivers cost-effective, high-accuracy detection and enables efficient coverage of the genome at scale, making it the standard for high-volume, high-accuracy genomic studies. The limitation appears when sequencing repetitive genomic regions or when trying to understand how distant genomic elements relate to one another.  

Long-read sequencing takes the panoramic view, generating reads that span tens of thousands of base pairs at once. This extended context can resolve complex structural variations and repetitive genomic regions that remain challenging with shorter reads.2  However, this level of resolution comes with specific considerations for throughput, cost, and data analysis.  

 

Short-Read WGS: Scalable Genome Analysis 

Short-read whole genome sequencing has become the foundation of large-scale genomics research, offering a powerful combination of accuracy, throughput, and affordability. This approach provides comprehensive detection of point mutations and small genetic changes across the entire genome, along with small copy number variations and high-confidence variant calling in most genomic regions.1   

The approach has proven particularly valuable for applications requiring the analysis of hundreds or thousands of samples. Population genetics studies and genome-wide association studies (GWAS) represent prime applications for short-read WGS, where the ability to sequence large cohorts cost-effectively enables researchers to identify genetic variants associated with complex traits and diseases. In cancer genomics, short-read sequencing facilitates the identification of somatic mutations, the tracking of tumor evolution, and the discovery of therapeutic targets. Pharmacogenomics researchers use these tools to understand how genetic variation influences drug response across patient populations, while disease gene discovery programs use short-read WGS to identify pathogenic variants in protein-coding regions and well-characterized regulatory elements.3,4

Beyond its scientific capabilities, short-read sequencing offers practical advantages that make it suitable for diverse research contexts. The technology generally provides faster turnaround times that can support clinical decision-making. Short-read platforms are more accommodating of challenging sample types, including low-input or degraded DNA such as formalin-fixed paraffin-embedded (FFPE) tissue or cell-free DNA (cfDNA). The high throughput of modern short-read platforms makes them ideal for large-scale projects where cost per sample is a critical consideration. 

 

Long-Read WGS: Decoding Genomic Complexity 

Despite the broad utility of short-read sequencing platforms, certain genomic features remain difficult to resolve without longer read lengths. Long-read WGS addresses this by providing enhanced resolution of structural complexity. This technology excels at detecting large structural variants, including insertions, deletions, inversions, and translocations that play important roles in both inherited and somatic disease. Complex structural rearrangements and large copy number variations become more clearly visible due to the extended context that long reads provide. 

This approach also enables researchers to phase variants by determining which genetic variations occur together on the same chromosome, providing haplotype information that can be critical for understanding inheritance patterns and disease risk. Furthermore, long-read sequencing can resolve disease-causing variants in genomic regions that are notoriously difficult to analyze, including highly repetitive sequences and certain non-coding regulatory regions.1  

Research applications that particularly benefit from long-read sequencing include structural variant analysis in developmental disorders and cancer, where large genomic changes can have profound effects on cellular function. De novo genome assembly projects rely on long reads to build reference genomes or characterize novel sequences. In complex disease genetics, long-read technologies have proven invaluable for resolving repeat expansions in neurological disorders and other complex or rare conditions where the causative variants may be structurally complex. 

While long-read sequencing offers powerful analytical capabilities, researchers should consider that it typically requires a higher per-sample investment compared to short-read approaches. Sample quality requirements can be more stringent, as longer, intact DNA molecules are needed to generate the extended reads. Additionally, specialized bioinformatics expertise may be helpful for certain applications, though analysis pipelines continue to mature and become more accessible. 

 

Making the Right Choice for Your Research 

Selecting between short-read and long-read WGS begins with clearly defining your research questions. What variant types are most likely to be relevant to your investigation? Are you primarily interested in common single nucleotide variants and small indels, or do you need to detect structural variants and resolve complex genomic regions? The answers to these questions will guide your sequencing approach. 

Study design considerations also play a critical role in this decision. For large cohort studies involving hundreds to thousands of samples, short-read WGS often provides better value, enabling you to maximize sample size within budget constraints. Conversely, smaller focused studies or projects requiring deep analysis of individual genomes may justify the higher per-sample investment of long-read sequencing. Sample quality and type are also deciding factors, as some specimen types work better with specific sequencing approaches, though custom sequencing services can often accommodate various sample types with appropriate protocols. 

Budget and timeline realities cannot be ignored. Total project budget influences how much can be invested per sample, which in turn affects the achievable sample size. Short-read sequencing’s lower per-sample cost enables testing of larger cohorts, while long-read sequencing requires higher per-sample investment but delivers unique data. Timeline constraints may also factor into your decision, as short-read sequencing generally offers faster turnaround times that can be important for time-sensitive research. 

Importantly, these approaches need not be mutually exclusive. Some research programs strategically combine both technologies, using short-read WGS for initial cohort screening and then applying targeted long-read sequencing to complex cases that require additional resolution. Clinical sequencing programs may employ short reads as first-tier testing with long-read follow-up for cases that remain unresolved. These hybrid strategies can maximize research insights while managing costs effectively. 

 

Comparison of WGS Sequencing Strategies 

Feature  Short-Read WGS  Long-Read WGS 
Read Length  Hundreds of base pairs.  Tens of thousands of base pairs. 
Primary Variant Detection  Point mutations, small indels, and small copy number variations.  Large structural variants (inversions, translocations) and repeat expansions. 
Genomic Resolution  High-accuracy detection in well-characterized regions.  Resolves highly repetitive and “dark” genomic regions. 
Phasing Capability  Limited ability to determine haplotypes.  Enables variant phasing to determine which variations occur on the same chromosome. 
Sample Requirements  Accommodates low-input or degraded DNA (e.g., FFPE, cfDNA).  Requires high-quality, long, intact DNA molecules. 
Ideal Study Scale  Large cohorts (hundreds to thousands of samples).  Focused studies or deep analysis of individual genomes. 
Economic Profile  Cost-efficient at scale.  Higher per-sample investment with unique data output. 
Turnaround Time  Generally faster turnaround times.  Can be longer due to specialized analysis requirements. 

 

Working with Experienced Sequencing Providers 

The complexity of modern genomics research makes partnership with experienced providers increasingly valuable. When selecting a sequencing partner, researchers should look for providers that offer both short-read and long-read capabilities, enabling access to the most appropriate technology for each aspect of a project. Quality assurance through CLIA-licensed and CAP-accredited facilities is important for clinical sequencing applications, while comprehensive support from study design through data analysis can help research teams navigate complex genomics workflows. 

 

Conclusion 

Sequencing capabilities are rapidly evolving and comprehensive genomic analysis is becoming more accessible than ever before. Short-read and long-read WGS technologies offer complementary approaches to genome analysis, each with distinct strengths. The right choice depends on your specific research questions, the variant types most relevant to your investigation, your study scale, and budget. In many cases, the optimal strategy may involve both technologies applied at different stages or to different samples within a research program. 

 As you plan your next human genomics project, consider consulting with Broad Clinical Labs, the leader in whole genome sequencing services, to discuss how different sequencing strategies might align with your research objectives. Understanding these technological options early in project planning enables you to design studies that maximize scientific impact while making efficient use of resources. 

For researchers ready to explore comprehensive WGS options for their programs, Broad Clinical Labs offers both short-read and long-read research and clinical sequencing services with expert support and consultation. Visit https://broadclinicallabs.org/whole-genome-sequencing to learn more. 

 

References: 

  1. Polonis, K. et al. “Innovations in Short-Read Sequencing Technologies and Their Applications to Clinical Genomics.” Clinical Chemistry (2025) 71(1):97-108. doi: 10.1093/clinchem/hvae173
  1. Logsdon, G.A. et al. “Long-read human genome sequencing and its applications.” Nature Reviews Genetics (2020) 21:597-614. doi: 10.1038/s41576-020-0236-x
  1. The All of Us Research Program Genomics Investigators. “Genomic Data in the All of Us Research Program.” Nature (2024) 627:340-346. doi: 10.1038/s41586-023-06957-x
  1. Venner, E. et al. “Whole-genome sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic results as part of the All of Us Research Program.” Genome Medicine (2022) 14:34. doi: 10.1186/s13073-022-01031-z

Return to the Blog

Sean Hofherr

Chief of Clinical Strategy and Product Development, Broad Clinical Labs

Sean Hofherr is dual board certified by ABMGG in Clinical Biochemical Genetics and Clinical Molecular Genetics. Sean serves as the Chief of Clinical Strategy and Product Development at Broad Clinical Labs. In this role at BCL, Sean is able to leverage his extensive experience to guide the clinical vision and delivery across the organization. Sean most recently served as the Chief Operating Office at Fabric Genomics, which focuses on the use of AI and Bioinformatics for Clinical Interpretation of whole genome sequencing. Prior to Fabric, Sean was the Chief Scientific Officer and CLIA Director at the commercial reference laboratory, GeneDx.

Sean received his B.S. degree in Microbiology and Cell Sciences from the University of Florida before earning his Ph.D. in Molecular and Human Genetics from Baylor College of Medicine. Sean completed clinical fellowships in Clinical Biochemical Genetics and Clinical Molecular Genetics at the Mayo Clinic.

Danielle Perrin

Chief of Staff, Broad Clinical Labs

As Broad Clinical Labs’ Chief of Staff, Danielle Perrin advises and supports colleagues on the executive leadership team in BCL’s strategic planning and execution. She builds and leads new organizational functions and processes and leads critical projects, as well as driving effective information flow, decision making, and execution throughout the organization. An operations leader with a business, engineering, and biology background and 20+ years of experience in the genomics field, Perrin has a track record of driving operational excellence and building and scaling both physical and business processes. During her career at Broad, which started in 2003 at the tail end of the Human Genome Project, Perrin has led laboratory operations and R&D teams in Broad’s Genomics Platform, as well as fulfilling senior advisory and leadership roles in the Broad Institute’s COO and CFO offices.

Perrin received her B.S. in Biology and M.E. in Biotechnology Engineering from Tufts University and her M.B.A. from the MIT Sloan School of Management.

Tim De Smet

Chief Commercial Officer, Broad Clinical Labs

As Chief Commercial Officer of Broad Clinical Labs, Tim De Smet leads BCL’s business development, alliance management, external project management, and customer support teams. A Broad Institute employee since 2008, De Smet has held leadership roles and managed teams of various sizes in Broad’s Genomics Platform and clinical lab, spanning laboratory operations, finance, and informatics, and has expertise in work design, financial modeling, and high scale laboratory and business operations.

De Smet received his B.S. in Biochemistry and M.B.A. from Northeastern University.

Jim Meldrim

Chief Technology Officer, Broad Clinical Labs

As Chief Technology Officer, Jim Meldrim sets the vision for Broad Clinical Labs’ informatics systems, including the hardware and software used for sample intake and tracking, data production, analysis, and delivery. Having held a variety of laboratory and informatics-focused leadership roles at Broad, spanning R&D and production operations, Meldrim has been a leader and innovator in the generation, management, and analysis of genomic data since 1999, beginning with sequencing data generation for the Human Genome Project.

Meldrim received his B.S. in Biology from Cornell University.

Sheila Dodge

Chief Operating Officer, Broad Clinical Labs

As Chief Operating Officer, Sheila Dodge leads Broad Clinical Labs’ process development and implementation activities, as well as lab operations, financial planning and operations, quality & compliance, and core business processes. A Six Sigma Black Belt with extensive experience in process development and high throughput genomics operations, Dodge is an expert in work design and in collaborating with a range of collaborators, scientists, engineers, and technology partners to rapidly integrate new technologies and operationalize innovations. A member of the Broad Institute since 2001, Dodge is an Institute Scientist and lectures at the MIT Sloan School of Management on operations, dynamic work design, and visual management techniques.

Dodge received her B.A. in biochemistry and molecular biology from Boston University and her master’s degree in biology from Harvard University. She earned her M.B.A. from MIT Sloan School of Management.

Heidi Rehm, Ph.D., FACMG

Chief Medical Officer and Clinical Laboratory Director, Broad Clinical Labs

Heidi Rehm is board-certified by ABMGG in Clinical Molecular Genetics and Genomics and serves as BCL’s Chief Medical Officer and Clinical Laboratory Director. She oversees BCL’s regulatory requirements, leads the clinical team performing genomic interpretation and variant analysis, and guides BCL’s efforts in genomic testing for clinical and research use. She is also an Institute Member of the Broad and co-director of the Medical and Population Genetics Program. Rehm is also the Chief Genomics Officer in the Department of Medicine and Genomic Medicine Unit Director at the Center for Genomic Medicine at Massachusetts General Hospital, working to integrate genomics into medical practice. She is a principal investigator of ClinGen, providing free and publicly accessible resources to support the interpretation of genes and variants. She co-leads both the Broad Center for Mendelian Genomics, focused on discovering novel rare disease genes, and the Matchmaker Exchange, which aids in gene discovery. She is Chair of the Global Alliance for Genomics and Health, a principal investigator of the Broad-LMM-Color All of Us Genome Center, co-leader of the Genome Aggregation Database (gnomAD), and a Board Member and Vice President of Laboratory Genetics for the American College of Medical Genetics and Genomics.

Rehm received her B.A. degree in molecular biology and biochemistry from Middlebury College before earning her M.S. in biomedical science from Harvard Medical School and Ph.D. in genetics from Harvard University. She completed her post-doctoral training with David Corey in neurobiology and a fellowship in clinical molecular genetics at Harvard Medical School.

Niall Lennon, Ph.D.

Chair and Chief Scientific Officer, Broad Clinical Labs

As Chair and Chief Scientific Officer of Broad Clinical Labs, Niall Lennon leads the team and sets the scientific and clinical vision for the organization. Dr. Lennon joined the Broad Institute in 2006 and has since contributed to the development of applications for every major massively parallel sequencing platform across a range of fields. In 2013 Dr. Lennon led the effort to establish a CLIA licensed, CAP-accredited clinical laboratory at the Broad Institute to facilitate return of results to patients and to support clinical trials. More recently, he has led efforts to achieve FDA approval for large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing operation, which returned 37+ million results to patients. Dr. Lennon is a principal investigator of the eMerge and All of Us projects, an Institute Scientist at Broad, Associate Director of Broad’s Gerstner Center for Cancer Diagnostics, and an adjunct professor of biomedical engineering at Tufts University, where he teaches Molecular Biotechnology.

Dr. Lennon received a Ph.D. in pharmacology from University College Dublin and completed his postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management.